ImmunoCellular Therapeutics, Ltd. announced consolidated earnings results for the fourth quarter and full year ended December 31, 2016. For the quarter, the company incurred a net loss of $6.3 million, or $1.36 per basic and diluted share, compared to a net loss of $4.8 million, or $2.13 per basic and diluted share, for the quarter ended December 31, 2015. For the year, the company incurred a net loss of $22.1 million, or $7.89 per basic and diluted share, compared to a net loss of $12.8 million, or $5.87 per basic and diluted share, for the year ended December 31, 2015. Cash used in operations was $19.9 million compared to $19.0 million in 2015. Loss before other income was $24,112,125 compared to $15,513,091 in 2015.